Preclinical Research – Page 5

Species selection questioned during regulatory submission prep – regulatory deficiency risk analysis

When species selection is questioned during the regulatory submission process, several symptoms or signals may emerge that indicate potential deficiencies in preclinical study design:Click to read the full article.

Dose justification weak during program hold risk review – how to defend preclinical package

Identifying symptoms or signals that indicate a weak dose justification during a program hold risk review is the first step in the investigative process. Such signals may arise from various…

Dose justification weak during study audit – preventing clinical hold

Identifying symptoms or signals related to weak dose justification during study audits is the first critical step in diagnosis and response. Some common indicators include:Click to read the full article.

Reproducibility gaps during IND-enabling studies – CAPA for study design gaps

Identifying reproducibility gaps in IND-enabling studies typically begins with recognizing signs of inconsistencies in data outputs. Symptoms may manifest as:Click to read the full article.

GLP readiness concerns during regulatory submission prep – how to defend preclinical package

Detecting GLP readiness concerns early is critical for mitigating risks during regulatory submissions. A variety of symptoms may signal underlying issues that need to be addressed:Click to read the full…

Non-clinical toxicity findings during IND-enabling studies – preventing clinical hold

Non-clinical toxicity findings can manifest through various signals in the laboratory environment. Understanding these early warning signs is critical to initiating a thorough investigation.Click to read the full article.

Non-clinical toxicity findings during regulatory submission prep – how to defend preclinical package

The first step in addressing non-clinical toxicity findings is recognizing the symptoms or signals that suggest the presence of issues. Symptoms can manifest during preclinical studies and may include:Click to…

GLP readiness concerns during IND-enabling studies – CAPA for study design gaps

Identifying symptoms or signals that indicate GLP readiness concerns is paramount in initiating a proactive investigation. Common signals include:Click to read the full article.

Reproducibility gaps during program hold risk review – FDA/EMA non-clinical expectations

Reproducibility gaps may exhibit various signals that can be identified on the laboratory floor during preclinical studies. Recognizing these symptoms early is paramount for timely intervention. Common signals include:Click to…

Reproducibility gaps during IND-enabling studies – FDA/EMA non-clinical expectations

Identifying the symptoms associated with reproducibility gaps is crucial for initiating a targeted investigation. Common signals encountered during IND-enabling studies may include:Click to read the full article.

Non-clinical toxicity findings during sponsor oversight – preventing clinical hold

Recognizing symptoms and signals indicating non-clinical toxicity findings is the first step toward intervention. These may manifest as unexpected adverse effects observed during preclinical studies, abnormal lab results, or significant…